Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
101.36
+1.29 (1.29%)
Feb 2, 2026, 9:53 AM EST - Market open
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,839,169
Profits / Employee
$454,178
Market Cap
19.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 6,772 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Insmed | 1,271 |
| Ionis Pharmaceuticals | 1,069 |
| Ascendis Pharma | 1,017 |
| Revolution Medicines | 809 |
| Roivant Sciences | 750 |
INCY News
- 3 days ago - Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
- 6 days ago - Incyte to Report Fourth Quarter and Year-End 2025 Financial Results - Business Wire
- 11 days ago - What Investors Should Know Before Buying Incyte - Seeking Alpha
- 16 days ago - Incyte: Buy For The Turnaround, Stay For The Pipeline - Seeking Alpha
- 17 days ago - Incyte's Pipeline Potential Signals Massive Upside For Investors - Seeking Alpha
- 17 days ago - Steven Cress' Top 10 Stocks For 2026 - Seeking Alpha
- 20 days ago - Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 26 days ago - Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins - Seeking Alpha